Helix BioPharma closes C$3,673,000 convertible debenture placement

Helix BioPharma Corp. closed a non-brokered private placement of unsecured convertible debentures, announced on June 3, 2026. The company issued 3,673 convertible debentures for aggregate gross proceeds of C$3,673,000.

The principal and any unpaid accrued interest are due 14 months from the closing date. Each debenture bears interest at 25.00% per annum, calculated on a simple interest basis.

If the debentures are not repaid by the maturity date, the outstanding principal may be converted by the holder into common shares at C$1.42 per share. That price is the market price as of the price reservation date, less the permitted 20% discount under TSX policies.

Any accrued but unpaid interest may also convert on the maturity date. The interest conversion price is the greater of the conversion price and the volume weighted average trading price of the shares on the TSX over the five trading days before the relevant date, less the TSX permitted discount.

The release describes the offering as non-brokered and names no placement agent or advisor.

Report an error